Onderneming CSL Limited

CSL

AU000000CSL8

Farmaceutische producten

Analistenconsensus

Vakgebied

Verkoop per activiteit

Verkoop per regio

Managers

Besturend

Aandelenklasse

Aandeelhouders

Participaties

Bedrijfsgegevens

Bedrijven van de groep

Sector

Verkoop per activiteit

Verkoop per regio

Ratings voor CSL Limited

Herzieningen van WPA

Kwartaalwinst - Afwijkingspercentage

Sector Biofarmaceutica

Beurs gesloten - Australian S.E. Andere beurzen 08:10:45 19-04-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
269,5 ^AUD	-0,70%		-3,89%	-5,99%

12:51	Vifor Pharma biedt aan om concurrentiebeperkend gedrag tegen rivaal recht te zetten	RE
10/04	Mijnbouw stimuleert Australische aandelen; NZ cenbank houdt rente stabiel	RE

CSL Limited is een in Australië gevestigd biotechnologiebedrijf. Het bedrijf richt zich op zeldzame en ernstige ziekten, griepvaccins, ijzertekort en nefrologie. De segmenten van het bedrijf omvatten CSL Behring, CSL Seqirus en CSL Vifor. Het CSL Behring segment produceert, verkoopt en distribueert plasmaproducten, gentherapieën en recombinanten. Het CSL Seqirus segment produceert, verkoopt en distribueert voornamelijk influenza gerelateerde producten en levert pandemische diensten aan overheden. Het CSL Vifor segment produceert, verkoopt en distribueert producten in de therapeutische gebieden ijzertekort en nefrologie. CSL Plasma exploiteert plasma-inzamelnetwerken met meer dan 325 plasma-inzamelcentra in de Verenigde Staten, Europa en China. Het bedrijf is actief in Australië, de Verenigde Staten, Duitsland, het Verenigd Koninkrijk, Zwitserland en China. Haar producten omvatten Respreeza, Zemaira, HAEGARDA, KCENTRA, Hepatitis B, Evogam en andere.

Aantal werknemers: 32 065

AUD in miljoen	2022	Gewicht	2023	Gewicht	Delta
CSL Behring 69,8 %	11 857	81,4 %	13 811	69,8 %	+16,48%
CSL Seqirus 15,3 %	2 708	18,6 %	3 019	15,3 %	+11,52%
CSL Vifor 14,9 %	-	-	2 957	14,9 %	-

AUD in miljoen	2022	Gewicht	2023	Gewicht	Delta
United States 49,3 %	7 065	48,5 %	9 757	49,3 %	+38,10%
Rest of World 21,4 %	2 776	19,1 %	4 236	21,4 %	+52,59%
Australia 7,9 %	1 409	9,7 %	1 554	7,9 %	+10,23%
Germany 6,5 %	1 077	7,4 %	1 292	6,5 %	+19,93%
China 5,9 %	1 027	7,0 %	1 158	5,9 %	+12,79%
United Kingdom 5,4 %	822	5,6 %	1 066	5,4 %	+29,68%
Switzerland 3,7 %	388	2,7 %	725	3,7 %	+86,90%

Managers	Titel	Leeftijd	Van
Paul McKenzie CEO	Chief Executive Officer	58	01-06-19
Joy Carolyn Linton DFI	Director of Finance/CFO	59	01-10-20
Mark Hill CTO	Chief Tech/Sci/R&D Officer	62	01-10-20
William Mezzanotte CTO	Chief Tech/Sci/R&D Officer	66	01-10-18
Andrew Nash CTO	Chief Tech/Sci/R&D Officer	-	01-11-06
Andrew Cuthbertson BRD	Director/Board Member	70	01-03-97
Mark Dehring IRC	Investor Relations Contact	-	-
Kate Priestman PRN	Corporate Officer/Principal	-	11-09-23
Ken Lim PRN	Corporate Officer/Principal	50	01-01-13
Bill Campbell PRN	Corporate Officer/Principal	64	01-01-14

Besturend	Titel	Leeftijd	Van
Carolyn Hewson BRD	Director/Board Member	69	09-12-19
Brian McNamee PSD	President	68	01-07-90
Alison Watkins BRD	Director/Board Member	61	19-08-21
Andrew Cuthbertson BRD	Director/Board Member	70	01-03-97
Megan Clark BRD	Director/Board Member	66	16-02-16
Marie McDonald BRD	Director/Board Member	68	14-08-13
Sam Lewis BRD	Director/Board Member	-	01/01
Duncan Maskell BRD	Director/Board Member	63	18-08-21
Paul McKenzie CEO	Chief Executive Officer	58	01-06-19

	Stemming	Aantal	Vrij verhandelbaar	Bedrijfseigen aandelen	Drijvend Totaal
Aandeel A	1	483 093 257	480 846 726 ( 99,53 %)	0	99,53 %

Naam	Aandelen	%	Totale waarde
State Street Global Advisors Trust Co. 1,107 %	5 349 487	1,107 %	1 005 M $
Colonial First State Investments Ltd. 0,9797 %	4 734 581	0,9797 %	889 M $
Commonwealth Superannuation Corp. (Investment Management) 0,6784 %	3 278 217	0,6784 %	616 M $
Netwealth Investments Ltd. 0,5316 %	2 568 812	0,5316 %	483 M $
Australian Foundation Investment Co. Ltd. (Invt Mgmt) 0,5030 %	2 431 000	0,5030 %	457 M $
BetaShares Capital Ltd. 0,3329 %	1 608 787	0,3329 %	302 M $
AMP Capital Investors Ltd. 0,2738 %	1 322 973	0,2738 %	249 M $
Argo Investments Ltd. (Investment Management) 0,2594 %	1 253 509	0,2594 %	235 M $
State Street Global Advisors Ltd. 0,2178 %	1 052 335	0,2178 %	198 M $
Australian Eagle Asset Management Pty Ltd. 0,2019 %	975 763	0,2019 %	183 M $

Naam	Aandelen	%	Totale waarde
SILVERCREST ASSET MANAGEMENT GROUP INC. 0,006264 %	60 545	0,006264 %	6 M $
Boston Common Asset Management LLC 0,004533 %	43 811	0,004533 %	4 M $
Domini Impact Investments LLC 0,003321 %	32 100	0,003321 %	3 M $
Yousif Capital Management LLC 0,001762 %	17 030	0,001762 %	2 M $
RhumbLine Advisers LP 0,001472 %	14 227	0,001472 %	1 M $
Budapest Fund Management Co. Ltd. 0,000507 %	4 901	0,000507 %	460 302 $
SVB Wealth LLC 0,000405 %	3 919	0,000405 %	368 072 $
GAMMA Investing LLC 0,000171 %	1 652	0,000171 %	155 156 $
Ametos Invest GmbH 0,000124 %	1 200	0,000124 %	112 704 $
PNC Investments LLC 0,000017 %	161	0,000017 %	15 121 $

Naam	Aandelen	%	Totale waarde
CARA THERAPEUTICS, INC. 13.53%	7 396 770	13.53%	6 731 061 $

CSL Ltd.

655 Elizabeth Street

3000, Melbourne

+61 3 9389 1911

http://www.csl.com.au

Naam	Categorie en sector
CSL Behring LLC CSL Behring LLC BiotechnologyHealth Technology CSL Behring LLC researches, develops, manufactures, and markets biotherapies that are used to treat serious and rare conditions. It offers protein-based therapies in the areas of Bleeding Disorders, Fluid Replacement, Hereditary Angioedema, Immunoglobulin, Pulmonary, and Wound Healing Therapies. The company was founded in 2004 and is headquartered in King of Prussia, PA.	Biotechnology
CSL Behring AG CSL Behring AG BiotechnologyHealth Technology Part of CSL Ltd., CSL Behring AG is a Swiss company that develops biological products. The private company is based in Bern, Switzerland.	Biotechnology
CSL Behring UK Ltd. CSL Behring UK Ltd. Pharmaceuticals: MajorHealth Technology Part of CSL Ltd., CSL Behring UK Ltd. is a private company that manufactures and supplies plasma therapies. The company is based in Haywards Heath, UK. The British company was founded in 1916 by Emil von Behring.	Pharmaceuticals: Major
CSL Behring GmbH CSL Behring GmbH Pharmaceuticals: MajorHealth Technology Part of CSL Ltd., CSL Behring GmbH is a German company that actively collaborates to develop special programs and activities for patients with rare diseases. The private company is based in Marburg, Germany. The CEOs of the company are Lutz Guenter Bonacker, Michael Schröder, Craig Shelanskey.	Pharmaceuticals: Major
CSL Behring Beteiligungs- und Verwaltungs GmbH & Co. KG CSL Behring Beteiligungs- und Verwaltungs GmbH & Co. KG Pharmaceuticals: MajorHealth Technology Part of CSL Ltd., CSL Behring Beteiligungs- und Verwaltungs GmbH & Co. KG is a German pharmaceutical company that manufactures pharmaceutical products. The private company is based in Marburg, Germany. The company was founded in 2004. The CEO is Craig Shelanskey.	Pharmaceuticals: Major
CSL Plasma GmbH CSL Plasma GmbH Medical/Nursing ServicesHealth Services CSL Plasma GmbH provides plasma collection and donation services. It specializes in the collection, testing, and management of plasma taken from blood donors. It focuses on the use of plasma as a key ingredient for products crucial to treating patients suffering from hemophilia, shock or trauma, immune deficiencies, and other blood disorders. It operates through its testing laboratories, collection facilities, and logistics centers. The company is headquartered in Marburg, Germany.	Medical/Nursing Services
CSL Finance GmbH CSL Finance GmbH Financial ConglomeratesFinance Part of CSL Ltd., CSL Finance GmbH is a German company that provides investment services. The private company is based in Marburg, Germany. The CEOs are Dieter Engstfeld, Antje Michel, Craig Shelanskey. The company was founded in 2014.	Financial Conglomerates
CSL Behring Recombinant Facility AG CSL Behring Recombinant Facility AG BiotechnologyHealth Technology Part of CSL Ltd., CSL Behring Recombinant Facility AG is a Swiss biotherapeutics company that develops and delivers innovative therapies to improve patients' lives. The private company is based in Bern, Switzerland and has a manufacturing site there. The company's portfolio includes a wide range of recombinant and plasma-derived products.	Biotechnology
CSL Behring Lengnau AG

Trading rating

Beleggingsrating

ESG Refinitiv

A-

Meer adviezen

Verkoop

Koop

Gemiddeld advies

Accumuleren

Aantal analisten

Laatste slotkoers

173,5 USD

Gemiddelde koersdoel

199,5 USD

Spread / Gemiddelde doel

+14,99%

Consensus

Bedrijfscijfers

De agenda van het bedrijf

Gezondheidszorg

Farmaceutisch en medisch onderzoek

Farmaceutische producten

Farmaceutische producten

Biofarmaceutica

	Vaira. 1 jan.	Kapi.
CSL LIMITED	-5,99%	84,46 mld.
SAMSUNG BIOLOGICS CO.,LTD.	+2,76%	40,85 mld.
BIOGEN INC.	-25,67%	27,69 mld.
UCB	+53,61%	24,28 mld.
BIOMARIN PHARMACEUTICAL INC.	-7,81%	17,09 mld.
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-33,74%	13,67 mld.
INCYTE CORPORATION	-16,45%	11,86 mld.
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-11,19%	11,79 mld.
SWEDISH ORPHAN BIOVITRUM AB	-2,25%	8,07 mld.
INTRA-CELLULAR THERAPIES, INC.	+2,51%	7,51 mld.

Biofarmaceutica